VALN - Valneva to test COVID-19 shot against Omicron variant

Valneva SE (VALN -0.2%) announced that the company will test its experimental COVID-19 vaccine, VLA2001, against the newly found Omicron variant of coronavirus. However, it also noted that, as opposed to the vaccines that target only the spike protein of the virus, its whole-virus inactivated vaccine is based on the full SARS-CoV-2 virus envelope with a potential for a broader immune response. The presence of CpG1018 adjuvant is also expected to strengthen its effect against new COVID-19 variants by raising the T cell response in the immune system, according to the company. Valneva says it can refine the vaccine platform to address the threat of new variants. In the press release, the company confirmed that the European regulators have started the real-time review of its vaccine candidate. Based on CpG 1018 adjuvant from Dynavax Technologies (NASDAQ:DVAX), VLA2001 generated a superior antibody response compared to AstraZeneca's (NASDAQ:AZN) vaccine, Valneva (NASDAQ:VALN) said in

For further details see:

Valneva to test COVID-19 shot against Omicron variant